List view / Grid view

Ovarian Cancer

 

Lynparza Phase III data demonstrates progression-free survival in ovarian cancer

17 March 2017 | By Niamh Marriott, Junior Editor

AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…

Send this to a friend